CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice

Antonio Citro, Andrea Valle, Elisa Cantarelli, Alessia Mercalli, Silvia Pellegrini, Daniela Liberati, Luisa Daffonchio, Olga Kastsiuchenka, Pier Adelchi Ruffini, Manuela Battaglia, Marcello Allegretti, Lorenzo Piemonti

Onderzoeksoutput: Articlepeer review

60 Citaten (Scopus)

Samenvatting

Chemokines and their receptors have been associated with or implicated in the pathogenesis of type 1 diabetes (T1D), but the identification of a single specific chemokine/receptor pathway that may constitute a suitable target for the development of therapeutic interventions is still lacking. Here, we used multiple low-dose (MLD) streptozotocin (STZ) injections and the NOD mouse model to investigate the potency of CXCR1/2 inhibition to prevent inflammation- and autoimmunity-mediated damage of pancreatic islets. Reparixin and ladarixin, noncompetitive allosteric inhibitors, were used to pharmacologically blockade CXCR1/2. Transient blockade of said receptors was effective in preventing inflammation-mediated damage in MLD-STZ and in preventing and reversing diabetes in NOD mice. Blockade of CXCR1/2 was associated with inhibition of insulitis and modification of leukocytes distribution in blood, spleen, bone marrow, and lymph nodes. Among leukocytes, CXCR2(+) myeloid cells were the most decreased subpopulations. Together these results identify CXCR1/2 chemokine receptors as "master regulators" of diabetes pathogenesis. The demonstration that this strategy may be successful in preserving residual β-cells holds the potential to make a significant change in the approach to management of human T1D.

Originele taal-2English
Pagina's (van-tot)1329-1340
Aantal pagina's12
TijdschriftDiabetes
Volume64
Nummer van het tijdschrift4
DOI's
StatusPublished - apr 2015

Vingerafdruk

Duik in de onderzoeksthema's van 'CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice'. Samen vormen ze een unieke vingerafdruk.

Citeer dit